KPV and the published anti-inflammatory research

A tripeptide with an interesting preclinical profile — and a regulatory status that matters before you go any further.

TL;DR

• KPV is a three-amino-acid fragment (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring peptide involved in inflammatory regulation.
• Animal and cell-culture studies have associated KPV with reduced inflammatory markers in models of colitis and inflammatory bowel conditions.
• FDA removed KPV from Category 2 on April 22, 2026. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list.

What it is

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid peptide produced by the pituitary gland. Among its documented roles is modulation of inflammatory responses — a function that has drawn research interest for decades. KPV is the C-terminal tripeptide fragment of alpha-MSH: the three amino acids at the end of the chain — lysine (K), proline (P), and valine (V).

Researchers began isolating this fragment to understand which portion of alpha-MSH carries its anti-inflammatory properties and whether a smaller, more stable version could be studied independently. KPV is entirely synthetic in its research form.

How it works

KPV is studied for its proposed interaction with melanocortin receptors — particularly MC1R and MC3R — which are expressed on immune cells including macrophages and monocytes. In cell-culture and animal studies, KPV has been associated with downregulation of pro-inflammatory cytokines including NF-κB pathway signaling.

A study published in Gastroenterology by Luyer et al. and subsequent work by Kannengiesser and colleagues examined KPV in colitis models, finding reduced mucosal inflammation markers in mouse models of experimentally induced colitis (Kannengiesser et al., Inflammatory Bowel Diseases, 2008). The authors note the findings are in animal models and that translation to human outcomes requires formal clinical evaluation.

Who asks about it

KPV comes up most often in the context of inflammatory bowel disease, Crohn's disease, and other gastrointestinal conditions where people are searching for emerging research options beyond conventional pharmaceuticals. It also appears in longevity and gut-health research forums. The honest starting point for anyone asking about KPV in 2026 is the regulatory status — which limits legitimate access.

What the research says

The published literature on KPV consists primarily of in vitro (cell culture) and in vivo (animal model, primarily rodent) studies. The Kannengiesser et al. 2008 study in Inflammatory Bowel Diseases is among the most cited, examining colitis models in mice and reporting reductions in macroscopic and histological inflammation scores compared to controls.

More recent nanotechnology research has explored KPV delivery via nanoparticles for potential oral administration, with preclinical results published in Nature Materials (Laroui et al., 2014) demonstrating colitis reduction in mouse models using KPV-loaded hydrogel nanoparticles (Laroui et al., Nature Materials, 2014). This work reflects the research trajectory — still preclinical, still animal-model, but drawing serious scientific attention.

No published, peer-reviewed human clinical trial for KPV has been indexed in PubMed as of this writing.

What to know before considering it

FDA removed KPV from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.

The Halftime POV

KPV represents exactly the kind of research-stage compound that requires patience and regulatory awareness. The preclinical science is genuinely interesting — particularly the gut inflammation research — and the July 2026 advisory committee vote is worth watching. But the right response to interesting preclinical data is not to source an unverified compound online. It is to monitor the regulatory process and access compounds like KPV through licensed clinical channels once that pathway opens.

---

Related reading:

• Category 1 Vs Category 2
• Rfk Peptide Reclassification
• Bpc 157 Category 2

FAQ

Q: What is KPV? A: KPV is a tripeptide — three amino acids: lysine (K), proline (P), and valine (V) — derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It is a synthetic research compound studied primarily in animal and cell-culture models of inflammatory conditions.

Q: Is KPV available through a compounding pharmacy? A: FDA removed KPV from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, KPV is not in any FDA 503A category and is not on the 503A bulks list. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding KPV to the Section 503A bulk drug substances list. The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

Q: What does the research show about KPV? A: Published research on KPV consists primarily of in vitro and animal model studies. The Kannengiesser et al. 2008 study in Inflammatory Bowel Diseases documented reduced inflammation markers in mouse colitis models. A 2014 Nature Materials study showed similar results using KPV-loaded nanoparticles. No published human clinical trial exists as of this writing.

---

Disclaimer

KPV — discussed in this article — was previously in FDA's Category 2. FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• Kannengiesser K, et al. Melanocyte-stimulating hormone-related peptides mediate anti-inflammatory effects. Inflammatory Bowel Diseases, 2008.
• Laroui H, et al. Fab'-bearing siRNA TNF-alpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. Nature Materials, 2014.
• FDA 503A Bulk Drug Substances Category 2 List

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.